Skip to Main Content

Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the cloudy skies looming over the Pharmalot campus. After all, the birds are still chirping and a pleasant breeze is wafting by. So this calls for a cup or three of stimulation. Remember, no prescription is required. Our choice today is bananas Foster. Yes, this is a real thing. Meanwhile, here are a few items of interest. Have a grand day, and drop us a line if you hear something saucy. …

Ending the latest chapter in a years-long legal battle over who invented CRISPR, the U.S. Patent and Trademark Office ruled that the revolutionary genome editing technology belongs to the Broad Institute of Harvard and MIT, STAT explains. The decision is a blow to the University of California and biotech companies that had licensed the technology from the university for use in developing treatments, including Intellia Therapeutics (NTLA) and CRISPR Therapeutics (CRSP). They will now have to negotiate with the Broad Institute for the right to use CRISPR for human therapies.


A federal judge in Chicago rejected an Eli Lilly (LLY) bid to end a whistleblower lawsuit that accused the company of shortchanging the Medicaid Rebate Program between 2005 and 2016, Reuters writes. U.S. District Judge Harry Leinenweber ruled that plaintiff Ronald Streck cleared the first of four hurdles under the False Claims Act by establishing Lilly made false statements to the U.S. Centers for Medicare and Medicaid Services about prices charged distributors for its drugs. Streck, a lawyer and pharmacist with a long background in negotiating drug distribution agreements, has filed and settled several other such suits against drugmakers for allegedly shortchanging Medicaid.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.